Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Chenguang Biotech Group
300138
5
Shanghai Menon Animal Nutrition Technology
301156
CN Stock MarketDetailed Quotes
300782 Maxscend Microelectronics
- 73.73
- +2.47+3.47%
Trading Apr 8 09:41 CST
39.41BMarket Cap98.05P/E (TTM)
74.78High73.01Low22.85KlotVolume73.10Open71.26Pre Close168.95MTurnover0.51%Turnover Ratio98.05P/E (Static)534.55MShares131.0052wk High3.86P/B33.00BFloat Cap58.6152wk Low85.51Limit Up447.59MShs Float339.59Historical High57.01Limit Down2.48%Amplitude6.61Historical Low0.22Dividend TTM73.93Avg Price8.93KlotAsk0.30%Div YieldTTM100Lot Size10.71KlotBid
Maxscend Microelectronics Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Goods sale service render cash | 7.46%4.84B | 6.83%3.38B | 27.58%2.44B | 37.14%1.34B | 13.04%4.5B | -4.51%3.17B | -16.86%1.91B | -18.99%979.18M | -11.57%3.98B | -0.39%3.32B |
| Refunds of taxes and levies | 16.72%252.06M | 51.82%221.18M | 35.88%156.14M | 63.80%91.85M | -68.18%215.96M | -75.92%145.68M | -75.33%114.91M | -40.45%56.07M | 73.70%678.76M | 133.47%604.92M |
| Cash received relating to other operating activities | -2.24%249.23M | 73.54%239.19M | 69.59%76.93M | 22.94%26.58M | 186.41%254.95M | 112.42%137.83M | -4.89%45.36M | -34.96%21.62M | -60.47%89.02M | 170.14%64.89M |
| Cash inflows from operating activities | 7.37%5.34B | 11.40%3.84B | 28.96%2.67B | 38.26%1.46B | 4.68%4.97B | -13.45%3.45B | -26.33%2.07B | -20.90%1.06B | -7.21%4.75B | 10.34%3.99B |
| Goods services cash paid | 77.86%3.89B | 128.18%3.31B | 251.48%2.3B | 228.10%1.06B | -28.46%2.19B | -47.08%1.45B | -63.55%653.78M | -66.77%324.39M | -8.89%3.06B | 21.96%2.74B |
| Staff behalf paid | 31.74%650.95M | 32.77%505.34M | 34.32%332.8M | 24.61%187.82M | 37.07%494.1M | 52.08%380.6M | 70.33%247.76M | 54.09%150.72M | 117.91%360.48M | 116.56%250.26M |
| All taxes paid | -8.06%86.95M | -9.59%82.19M | -11.18%77.62M | 49.96%5.35M | -54.10%94.57M | -55.24%90.91M | -56.21%87.39M | 352.88%3.57M | 81.39%206.03M | 80.14%203.08M |
| Cash paid relating to other operating activities | 108.08%633.86M | 58.12%312.71M | 120.05%254.46M | 151.86%127.7M | 63.21%304.63M | 45.89%197.77M | 32.19%115.64M | 34.88%50.7M | -44.79%186.65M | -22.42%135.56M |
| Cash outflows from operating activities | 70.81%5.26B | 98.60%4.21B | 168.23%2.96B | 161.66%1.39B | -19.15%3.08B | -36.34%2.12B | -50.38%1.1B | -52.41%529.38M | -4.08%3.81B | 25.64%3.33B |
| Net cash flows from operating activities | -95.76%80.28M | -127.53%-366.27M | -129.82%-288.88M | -85.58%76.06M | 101.02%1.89B | 102.61%1.33B | 64.65%968.81M | 135.74%527.48M | -18.05%942.24M | -31.77%656.58M |
| Investing cash flow | ||||||||||
| Cash received from disposal of investments | -97.86%1.06M | --1.06M | --1.12M | --916.44K | -62.80%49.42M | ---- | ---- | ---- | -95.96%132.84M | -96.86%57.7M |
| Cash received from returns on investments | ---- | ---- | ---- | ---- | ---- | 106.97%2M | --1.04M | ---- | ---- | -96.27%967.43K |
| Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | -46.63%59.68M | -45.72%59.71M | -91.65%9.19M | -97.45%2.8M | 223,562.80%111.83M | 219,910.00%110.01M | --110.01M | --110.01M | 4,246.16%50K | 3,746.15%50K |
| Cash received relating to other investing activities | 456.49%122.99M | --177.85M | --138.04M | ---- | -48.35%22.1M | ---- | ---- | ---- | 116.37%42.79M | 7,035.74%1.06B |
| Cash inflows from investing activities | 0.21%183.73M | 113.03%238.61M | 33.59%148.35M | -96.62%3.72M | 4.37%183.35M | -89.95%112.01M | -87.83%111.05M | 1,022.50%110.01M | -94.76%175.68M | -40.60%1.11B |
| Cash paid to acquire fixed assets intangible assets and other long-term assets | -11.96%1.87B | 44.45%1.78B | 54.27%1.37B | 76.93%515.48M | 24.03%2.12B | -37.51%1.23B | -41.56%887.67M | -67.73%291.35M | -40.15%1.71B | 11.29%1.97B |
| Cash paid to acquire investments | -82.56%15M | -81.93%15M | -81.01%15M | ---- | 56.27%86M | 53.61%83M | 60.93%79M | ---- | -98.29%55.03M | -97.90%54.03M |
| Cash paid relating to other investing activities | -58.00%112.52M | -47.40%20.49M | -34.75%20.49M | ---- | 822.20%267.92M | -91.89%38.95M | -92.35%31.4M | ---- | -95.36%29.05M | 186.09%480.5M |
| Cash outflows from investing activities | -19.39%2B | 34.04%1.81B | 40.77%1.4B | 76.93%515.48M | 37.94%2.48B | -45.98%1.35B | -49.56%998.07M | -76.88%291.35M | -73.23%1.79B | -44.46%2.5B |
| Net cash flows from investing activities | 20.96%-1.81B | -26.91%-1.57B | -41.66%-1.26B | -182.20%-511.76M | -41.58%-2.29B | 10.67%-1.24B | 16.83%-887.02M | 85.50%-181.35M | 51.75%-1.62B | 47.21%-1.39B |
| Financing cash flow | ||||||||||
| Cash received from capital contributions | 158.19%45.6M | 955.21%43.86M | 955.21%43.86M | ---- | 211.33%17.66M | -7.62%4.16M | -7.62%4.16M | -7.62%4.16M | -99.81%5.67M | -99.85%4.5M |
| Cash from borrowing | --2.9B | --2.27B | --1.77B | --712.88M | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash received relating to other financing activities | 18.76%1.19M | 4.97%1.05M | 4.97%1.05M | ---- | 0.00%1M | --1M | --1M | ---- | --1M | ---- |
| Cash inflows from financing activities | 15,667.96%2.94B | 44,850.64%2.32B | 35,151.72%1.82B | 17,051.18%712.88M | 179.66%18.66M | 14.61%5.16M | 14.61%5.16M | -7.62%4.16M | -99.78%6.67M | -99.85%4.5M |
| Borrowing repayment | --368.96M | --165.96M | --165.96M | --135.96M | ---- | ---- | ---- | ---- | ---- | ---- |
| Dividend interest payment | 67.55%152.04M | 49.84%135.97M | 38.04%125.27M | --785.63K | -61.14%90.75M | -61.14%90.75M | -44.86%90.75M | ---- | 26.01%233.51M | 26.01%233.51M |
| Cash payments relating to other financing activities | -31.87%14.67M | 3.03%9.55M | 103.93%8.48M | 2.66%1.2M | 270.02%21.53M | 452.61%9.27M | 324.94%4.16M | --1.17M | -19.28%5.82M | -35.90%1.68M |
| Cash outflows from financing activities | 377.08%535.67M | 211.43%311.48M | 215.80%299.7M | 11,706.95%137.94M | -53.09%112.28M | -57.47%100.02M | -42.68%94.9M | --1.17M | 24.31%239.33M | 25.15%235.19M |
| Net cash flows from financing activities | 2,671.15%2.41B | 2,215.08%2.01B | 1,791.44%1.52B | 19,140.69%574.94M | 59.76%-93.62M | 58.88%-94.86M | 44.28%-89.75M | -33.58%2.99M | -108.37%-232.66M | -108.28%-230.69M |
| Net cash flow | ||||||||||
| Exchange rate change effecting cash and cash equivalents | 204.59%1.89M | -30.50%10.17M | -105.75%-1.83M | 72.13%-6.11M | -101.74%-1.81M | -78.84%14.63M | -58.03%31.74M | -88.34%-21.91M | 454.38%104.01M | 518.52%69.14M |
| Net increase in cash and cash equivalents | 237.20%677.31M | 680.00%76.14M | -223.02%-29.26M | -59.32%133.13M | 38.72%-493.65M | 101.09%9.76M | 104.22%23.79M | 131.65%327.22M | -247.90%-805.54M | -181.24%-893.51M |
| Add:Begin period cash and cash equivalents | -40.66%720.39M | -40.66%720.39M | -40.66%720.39M | -40.66%720.39M | -39.89%1.21B | -39.89%1.21B | -39.89%1.21B | -54.37%1.21B | 36.93%2.02B | 36.93%2.02B |
| End period cash equivalent | 94.02%1.4B | -34.91%796.52M | -44.17%691.13M | -44.62%853.51M | -40.66%720.39M | 8.68%1.22B | -14.99%1.24B | -5.27%1.54B | -39.89%1.21B | -56.27%1.13B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.